Antibacterial drug discovery - Then, now and the genomics future

Biochemical Pharmacology

Volumn 71, Issue 7, 2006, Pages 901-909

  Monaghan, Richard L ^a,b   Barrett, John F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Monatay Enterprises   (United States)

Author keywords

Antibacterials; Antibiotic synergy; Antibiotics; Drug discovery; Genomics; Pathogen response antibiotics; Resistance

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; ANTIINFECTIVE AGENT; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CIPROFLOXACIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DORIPENEM; ELACRIDAR; EP 013420; FROPENEM; GATIFLOXACIN; GEMIFLOXACIN; ICLAPRIM; LINEZOLID; MBI 594AN; MOXIFLOXACIN; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; ORITAVANCIN; PPI 0903M; PTK 0796; RAMOPLANIN; RIFALAZIL; RIFAMPICIN; RWJ 333441; TAK 599; TEBIPENEM; TELAVANCIN; TELITHROMYCIN; TIGACIL; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VRC 4887;

ANTIBIOTIC RESISTANCE; BACTERIAL GENETICS; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; EVOLUTIONARY ADAPTATION; HOST PATHOGEN INTERACTION; HOST SUSCEPTIBILITY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; STOMACH ULCER;

EID: 33644504461     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.11.023     Document Type: Article

References (90)

1. Tuberculosis. Fact Sheet March 2002 National Institute of Allergy and Infectious Diseases. Available at: http://www.niaid.nih.gov/factsheets/tb.htm. Accessed October 17, 2005.
2. M.A. Aziz, A. Wright, A. DeMynck, and A. Laszlo Anti-tuberculosis drug resistance in the world 2004 World Health Organization Geneva
3. I.M. Smith, and A.B. Vickers Natural history of 338 treated and untreated patients with staphylococcal septicaemia (1936-1955) Lancet 1 1960 1318 1322
4. Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments and emergency departments. Report Series 13-#143. Atlanta: National Center for Health Statistics - Center for Disease Control and Prevention; 1999.
5. NCT 00068120, ORWH:SCOR - Sex/gender factors affecting women's health, Sponsor - National Institute of Diabetes and Digestive and Kidney Diseases [Updated October 11, 2005 Accessed October 16, 2005]. Available at: http://www.ClinicalTrials.gov.
6. R.M. Major Fatal partners: war and disease 1941 Doubleday Doran & Co Garden City, NY
7. CDC Emergency Preparedness and Response: Bioterrorism Agents/Diseases. Available at: http://www.bt.cdc.gov/agent/agentlist.asp. Accessed July 27, 2005.
8. S.A. Haney, L.E. Alksne, P.M. Dunman, E. Murphy, and S.J. Projan Genomics in anti-infective drug discovery - getting to endgame Curr Pharm Des 8 13 2002 1099 1118
9. L.E. Bartholomew Isolation and characterization of Mycoplasma (PPLO) from patients with rheumatoid arthritis, systemic lupus erythematosus and Reiter's syndrome Arthritis Rheum 76 1965 376 388
10. C.S. Little, A. Bowe, R. Lin, J. Litsky, R.M. Fogel, and B.J. Balin Age alterations in extent and severity of experimental intranasal infection with Chlamydia pneumoniae in BALB/c mice Infect Immun 73 3 2005 1723 1734
11. A. Mantovani Cancer: inflammation by remote control Nature 435 7043 2005 752 753
12. T.M. Shallcross, B.J. Rathbone, J.I. Wyatt, and R.V. Heatley Helicobacter pylori associated chronic gastritis and peptic ulceration in patients taking non-steroidal anti-inflammatory drugs Aliment Pharmacol Ther 4 5 1990 515 522
13. S.N. Coulter, W.R. Schwan, E.Y. Ng, M.H. Langhorne, H.D. Ritchie, and S. Westbtock-Wadman Staphylococcus aureus genetic loci impacting growth and survival in multiple infection environments Mol Microbiol 30 1998 393 404
14. B. Weinrick, P.M. Dunman, F. McAleese, E. Murphy, S.J. Projan, and Y. Fang Effect of mild acid on gene expression in Staphylococcus aureus J Bacteriol 186 24 2004 8407 8423
15. K.E. Beenken, P.M. Dunman, F. McAleese, D. Macapagal, E. Murphy, and S.J. Projan Global gene expression in Staphylococcus aureus biofilms J Bacteriol 186 14 2004 4665 4684
16. J.A. Snyder, B.J. Haugen, E.L. Buckles, C.V. Lockatell, D.E. Johnson, and M.S. Donnenberg Transcriptome of uropathogenic Escherichia coli during urinary tract infection Infect Immun 72 2004 6373 6381
17. J.C. Betts, P.T. Lukey, L.C. Robb, R.A. McAdam, and K. Duncan Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling Mol Microbiol 43 3 2002 717 731
18. J.D. Isbister, K.L. Lauer, G.A. Molina, D. Lunsford, R.J. Guttendorf, and E.M. Rudnic Preliminary investigations of proteome, metabolome & transcriptone following amoxicillin treatments of S. pneumoniae 44th Interscience conference on antimicrobial agents and chemotherapy October 30-November 2, 2004, Abstract F-1542, Washington, DC 2004 American Society of Microbiology Washington, DC
19. S.A. Waksman The actinomycetes and their antibiotics Adv Appl Microbiol 175 1963 235 315
20. S.R. Bushby Combined antibacterial action in vitro of trimethoprim and sulphonamides. The in vitro nature of synergy Postgrad Med J 45 Suppl. 1969 10 18
21. E.B. Gottlin, R.E. Benson, S. Conary, B. Antonio, K. Duke, and E.S. Payne High-throughput screen for inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase by surrogate ligand competition J Biomol Screen 8 3 2003 332 339
22. D.E. Ehmann, J.E. Demeritt, K.G. Hull, and S.L. Fisher Biochemical characterization of an inhibitor of Escherichia coli UDP-N-acetylmuramyl-alanine ligase Biochim Biophys Acta 1698 2 2004 167 174
23. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J Pharmacol Toxicol Methods 44 2000 3 25
24. F.B. Dean, K. Gibson, R. Sabin, J.M. Bullard, H.G. Dallmann, and N. Janjic High throughput screen for inhibitors of Staphylococcus aureus DNA replication 44th Interscience conference on antimicrobial agents and chemotherapy October 30-November 2, 2004, Abstract F-1517, Washington, DC 2004 American Society of Microbiology Washington, DC
25. E.Z. Baum, S.M. Crespo-Carbone, R. Goldschmidt, D. Abbanat, B. Foleno, and E. Wira Inhibitors of MurF, an essential cell wall synthesis enzyme 44th Interscience conference on antimicrobial agents and chemotherapy October 30-November 2, 2004, Abstract F-1546, Washington, DC 2004 American Society of Microbiology Washington, DC
26. W.R. Strohl The role of natural products in a modern drug discovery program Drug Discov Today 5 2 2000 39 41
27. J. Owens Chris Lipinski discusses life and chemistry after the rule of five Drug Discov Today 8 1 2003 12 16
28. A. Ganesan Natural products as a hunting ground for combinatorial chemistry Curr Opin Biotechnol 15 6 2004 584 590
29. Sorensen D, McAlpine J, Piraee M, Farnet C, Zazopoulos E. Genome scanning technology reveals an antibacterial compound (ECO-0501) of a new structural class from the vancomycin-producer Amycolatopsis orientalis. In: 44th ICAAC, Washington, DC, Abstract F-720. American Society of Microbiology: Washington, DC, 2004.
30. W.D. Celmer, and B.A. Sobin The isolation of two synergistic antibiotics from a single fermentation source Antibiot Annu 3 1955-1956 1956 437 441
31. A. Canu, and R. Leclercq Overcoming bacterial resistance by dual target inhibition: the case of streptogramins Curr Drug Targets - Infect Disord 1 2 2001 215 225
32. R.K. Jha, and S.M. de Sousa High-throughput screen specific for inhibitors of E. coli PBP1b transpeptidase 44th Interscience conference on antimicrobial agents and chemotherapy October 30-November 2, 2004, Abstract F-1543, Washington, DC 2004 American Society of Microbiology Washington, DC
33. L. Silver, and K. Bostian Screening of natural products for antimicrobial agents Eur J Clin Microbiol Infect Dis 9 7 1990 455 461
34. A.T. Bull, A.C. Ward, and M. Goodfellow Search and discovery strategies for biotechnology: the paradigm shift Microbiol Mol Biol Rev 64 3 2000 573 606
35. J. Handelsman, M.R. Rondon, S.F. Brady, J. Clardy, and R.M. Goodman Molecular biological access to the chemistry of unknown soil microbes: a new frontier for natural products Chem Biol 5 10 1998 R245 R249
36. S.D. Bentley, K.F. Chater, A.M. Cerdeno-Tarraga, G.L. Challis, N.R. Thomson, and K.D. James Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2) Nature 417 2002 141 147
37. S. Donadio, M. Sosio, and G. Lancini Impact of the first Streptomyces genome sequence on the discovery and production of bioactive substances Appl Microbiol Biotechnol 60 2002 377 380
38. B. Hao, W. Gong, P.T. Rajagopalan, Y. Zhou, and D. Pei Structural basis for the design of antibiotics targeting peptide deformylase Biochemistry 38 15 1999 4712 4719
39. D.Z. Chen, D.V. Patel, C.J. Hackbarth, W. Wang, G. Dreyer, and D.C. Young Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor Biochemistry 39 2000 1256 1262
40. J.E. Bandow, D. Becher, K. Buttner, F. Hochgrafe, C. Freiberg, and H. Brotz The role of peptide deformylase in protein biosynthesis: a proteomic study Proteomics 3 2003 299 306
41. H. Fu, C. Dahlgren, and J. Bylund Subinhibitory concentrations of the deformylase inhiitor actinonin increase bacterial release of neutrophil activating peptides: a new approach to antimicrobial chemotherapy Antimicrob Agents Chemother 47 8 2003 2545 2550
42. K. Andries, P. Verhasselt, J. Guillemont, H.W.H. Gohlman, J-M. Neefs, and H. Winkler A Diarylquonoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 307 2005 223 227
43. NCT 00102947, Daptomycin in the treatment of patients with renal insufficiency and complicated skin and skin structure infections. Sponsor - Cubist Pharmaceuticals [Updated August 1, 2005; Accessed October 16, 2005]. Available at: http://www.ClinicalTrials.gov ; 2005.
44. NCT 00091819, Comparison of Telavancin and Vancomycin for complicated skin and skin structure infections with a focus on methicillin-resistant Staphylococcus aureus (Atlas 1). Sponsor - Theravance [Updated August 1, 2005; Accessed October 16, 2005]. Available at: http://www.ClinicalTrials.gov ; 2005.
45. D.K. Farver, D.D. Hedge, and S.C. Lee Ramoplanin: a lipoglycodepsipeptide antibiotic Ann Pharmacol 39 2005 863 868
46. C. Reading, and M. Cole Clavulanic acid: a beta-lactamase-inhibiting beta-lactam from Streptomyces clavuligerus Antimicrob Agents Chemother 1 5 1977 852 857
47. D. McDevitt, D.J. Payne, D.J. Holmes, and M. Rosenberg Novel targets for the future development of antibacterial agents J Appl Microbiol 92 Suppl. 2002 28S 34S
48. D. Yin, B. Fox, M.L. Lonetto, M.R. Etherton, D.J. Payne, and D.J. Holmes Identification of antimicrobial targets using a comprehensive genomic approach Pharmacogenomics 5 1 2004 101 113
49. A.A. Bianchi, and F. Baneyx Stress responses as a tool to detect and characterize the mode of action of antibacterial agents Appl Environ Microbiol 65 1999 5023 5027
50. E.B. Goh, G. Yim, W. Tsui, J. McClure, M.G. Surette, and J. Davies Transcriptional modulation of bacterial gene expression by subinhibitory concentrations of antibiotics Proc Natl Acad Sci USA 99 26 2002 17025 17030
51. W.H. Tsui, G. Yim, H.H. Wang, J.E. McClure, M.G. Surette, and J. Davies Dual effects of MLS antibiotics: transcriptional modulation and interactions on the ribosome Chem Biol 11 9 2004 1307 1316
52. B.L. Geller Antibacterial antisense Curr Opin Mol Ther 7 2 2005 109 113
53. Y. Ji, D. Yin, B. Fox, D.J. Holmes, and D. Payne Validation of antibacterial mechanism of action using regulated antisense RNA expression in Staphylococcus aureus FEMS Microbiol Lett 231 2 2004 177 184
54. W.-L. Ng, K.M. Kazmierczak, G.T. Robertson, R. Gilmour, and M.E. Winkler Transcriptional regulation and signature patterns revealed by microarray analysis of Streptococcus pneumoniae R6 challenged with sublethal concentrations of translation inhibitors J Bacteriol 185 1 2003 359 370
55. S. Utaida, P.M. Dunman, D. Macapagal, E. Murphy, S.J. Projan, and V.K. Singh Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon Microbiology 149 2003 2719 2732
56. J. Oiu, D. Zhou, Y. Han, L. Zhang, Z. Tong, and Y. Song Global gene expression profile of Yersinia pestis induced by streptomycin FEMS Microbiol Lett 243 2 2005 489 496
57. D. Ren, L.A. Bedzyk, P. Setlow, D.F. England, S. Kjelleberg, and S.M. Thomas Differential gene expression to investigate the effect of (5Z)-4-bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone on Bacillus subtilis Appl Environ Microbiol 70 8 2004 4941 4949
58. J.T. Lin, M.B. Connelly, C. Amolo, S. Otani, and D.S. Yaver Global transcriptional response of Bacillus subtilis to treatment with subinhibitory concentrations of antibiotics that inhibit protein synthesis Antimicrob Agents Chemother 49 5 2005 1915 1926
59. Y. Ji, B. Zhang, S.F. Van, P. Warren, G. Woodnutt, and Burnham MKR Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA Science 293 5538 2001 2266 2269
60. J.E. Bandow, H. Brotz, Leichert LIO, H. Labischinski, and M. Heckerl Proteomic approach to understanding antibiotic action Antimicrob Agents Chemother 47 3 2003 948 955
61. X. Li, M. Zolli-Juran, J.D. Cechetto, D.M. Daigle, G.D. Wright, and E.D. Brown Multicopy suppressors for novel antibacterial compounds reveal targets and drug efflux susceptibility Chem Biol 11 10 2004 1423 1430
62. P.M. Dunman, E. Murphy, S. Haney, D. Palacios, G. Tucker-Kellogg, and S. Wu Transcription profiling-based identification of Staphylococcus aureus genes regulated by the agr and/or sarA loci J Bacteriol 183 24 2001 7341 7353
63. S.M. Fortune, A. Jaeger, D.A. Sarracino, M.R. Chase, C.M. Sassetti, and D.R. Sherman Mutually dependent secretion of proteins required for mycobacterial virulence Proc Natl Acad Sci USA 102 2005 10676 10681
64. R. Pechous, L. Nagender, B.J. Wilkinson, and K. Jayaswal Regulation of the expression of cell wall stress stimulon member gene msrA1 in methicillin-susceptible or -resistant Staphylococcus aureus Antimicrob Agents Chemother 48 8 2004 3057 3063
65. J. Crofton, P. Chaulet, and D. Maher Principles for the management of drug resistant tuberculosis 1996 World Health Organization Geneva
66. J.M. Blondeau, and G.S. Tillotson Antibiotic dosing: do we dose to cure the individual or do we treat the greater societal needs? Therapy 2 4 2005 511 516
67. J.F. Acer Antibiotic synergy and antagonism Med Clin North Am 84 6 2000 1391 1406
68. L. Duncan, T. Doyle, Q. Du, J. Ehrhardt, A.S. Lynch, and K. Mdluli Construction of a novel Pseudomonas aeruginosa strain panel deficient in fifty-two potential drug efflux systems 44th Interscience conference on antimicrobial agents and chemotherapy October 30-November 2, 2004, Abstract F-1532, Washington, DC 2004 American Society of Microbiology Washington, DC
69. J. Kriengkauykiat, E. Porter, O. Lomovskaya, and A. Wong-Beringer Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multi-drug resistance in Pseudomonas aeruginosa Antimicrob Agents Chemother 49 2 2005 565 570
70. J. Fernandez, D. Abbanat, K. Bush, J. Hillard, Q. Guan, and X. Li In vivo efficacy of the bacterial type III protein secretion systems (TTPS) inhibitors JNJ-10275798 and JNJ-10278385 44th Interscience conference on antimicrobial agents and chemotherapy October 30-November 2, 2004, Abstract F-710, Washington, DC 2004 American Society of Microbiology Washington, DC
71. S. Gibbons, M. Oluwatuyi, and G.W. Kaatz A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus J Antimicrob Chemother 51 1 2003 13 17
72. M.G. Scott, and RE.W. Hancock Cationic antimicrobial peptides and their multifunctional role in the immune system Crit Rev Immunol 20 2000 407 431
73. D.M. Bowdish, D.J. Davidson, M.G. Scott, and R.E. Hancock Immunomodulatory activities of small host defense peptides Antimicrob Agents Chemother 49 5 2005 1727 1732
74. M.G. Scott, C.M. Rosenberger, M.R. Gold, B.B. Finlay, and R.E. Hancock An alpha-helical cationic antimicrobial peptide selectively modulates macrophage responses to lipopolysaccharide and directly alters macrophage gene expression J Immunol 165 6 2000 3358 3365
75. P.E. Charp, W.G. Rice, R.L. Raynor, E. Reimund, J.M.J. Kinkade, and T. Ganz Inhibition of protein kinase C by defensins, antibiotic peptides from human neutrophils Biochem Pharmacol 37 5 1988 951 956
76. J.L. Koehl, A. Muthaiyan, R.K. Jayaswal, K. Ehlert, H. Labischinski, and B.J. Wilkinson Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus Antimicrob Agents Chemother 48 10 2004 3749 3757
77. T.T. MacDonald, and G. Monteleone Immunity, inflammation, and allergy in the gut Science 307 2005 1920 1925
78. Obst U, Volkmann H, Schwartz T, Kirchen S. Oligonucleotide, method and system for detecting antibiotic resistance-mediating genes in microorganisms by means of real-time PCR. Patent US20050059064 A1; 2005.
79. M. Marin, D. deViedma, M.J. Ruiz-Serrano, and E. Bouza Rapid direct detection of multiple rifampin and isoniazid resistance mutations in Mycobacterium tuberculosis in respiratory samples by real-time PCR Antimicrob Agents Chemother 48 2004 4293 4300
80. S.S. Hegde, M.W. Vetting, S.L. Roderick, L.A. Mitchenall, and A. Maxwell A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA Science 308 2005 1480 1483
81. W.W. Weber Toxicogenomics: history and current applications ASM News 70 2004 364 370
82. M. Kinzig-Schippers, D. Tornalik-Scharte, A. Jetter, B. Scheidel, V. Jakob, and M. Rodamer Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 49 5 2005 1733 1738
83. J. Sandy, S. Holton, E. Fullam, E. Sim, and M. Noble Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis Protein Sci 14 3 2005 775 782
84. R.F. Service Going from genome to pill Science 308 2005 1858 1860
85. J.T. Sharp The Mycoplasmataceae (PPLO) as causes of joint infections Arthritis Rheum 118 1964 437 442
86. G.G. Zhanel, K. Homenuik, K. Nichol, A. Noreddin, L. Vercaigne, and J. Embil The glycylcyclines: a comparative review with the tetracyclines Drugs 4 1 2004 63 88
87. R. Chaudhry, N. Nisar, P. Malhotra, A. Kumar, and V.S. Chauhan Polymerase chain reaction confirmed Mycoplasma pneumoniae arthritis: a case report Indian J Pathol Microbiol 46 3 2003 433 436
88. C.P. Cannon, E. Braunwald, C.H. McCabe, J.T. Grayston, B. Muhlestein, and R.P. Giugliano Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome N Engl J Med 352 16 2005 1646 1654
89. J.T. Grayston, R.A. Kronmal, L.A. Jackson, A.F. Paris, J.B. Muhlestein, and J.D. Cohen Azithromycin for the secondary prevention of coronary events N Engl J Med 352 16 2005 1637 1645
90. J.L. Anderson Infection, antibiotics and atherothrombosis - end of the road or new beginnings? N Engl J Med 352 2005 1706 1709